Transcatheter Aortic Valve Replacement: State of the Art and Future Directions

Transcatheter aortic valve replacement (TAVR) is a transformational and rapidly evolving treatment for patients with aortic stenosis who require valve replacement. Novel technological advancements have made this percutaneous minimally invasive therapy a first-line treatment for many patients at extr...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2017-01, Vol.68 (1), p.15-28
Main Authors: Eleid, Mackram F, Holmes, David R
Format: Article
Language:English
Subjects:
Aortic Valve - abnormalities
Aortic Valve - physiopathology
Aortic Valve - surgery
aortic valve disease
Aortic Valve Insufficiency - surgery
Aortic Valve Stenosis - surgery
Bicuspid Aortic Valve Disease
Bioprosthesis - adverse effects
Coronary vessels
Forecasting
Heart surgery
Heart Valve Diseases - physiopathology
Heart Valve Diseases - surgery
Heart Valve Prosthesis - adverse effects
Humans
percutaneous therapy
Prosthesis Failure
Risk factors
TAVR
Transcatheter Aortic Valve Replacement - adverse effects
Transcatheter Aortic Valve Replacement - instrumentation
Transcatheter Aortic Valve Replacement - trends
transcutaneous aortic valve replacement
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transcatheter aortic valve replacement (TAVR) is a transformational and rapidly evolving treatment for patients with aortic stenosis who require valve replacement. Novel technological advancements have made this percutaneous minimally invasive therapy a first-line treatment for many patients at extreme risk for conventional cardiac surgery. New devices and improvements in existing devices have reduced procedural complications, and scientific trials are investigating the role of TAVR in lower-risk aortic stenosis populations, in patients with aortic regurgitation, and in patients with bicuspid aortic valve disease. Finally, there is intense interest in identifying patients in whom the risk-benefit ratio of TAVR is not favorable and should not be performed.
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev-med-101615-020427